Think HIPAA is the only privacy law healthcare marketers need to worry about? Think again. One of the biggest misconceptions in healthcare marketing is that HIPAA compliance equals privacy compliance. It doesn't. As consumer health data increasingly flows through websites, mobile apps, CRM platforms, advertising technologies, and AI-powered experiences, marketers are navigating a much more complex landscape. Depending on the data you're collecting—and how you're using it—state consumer privacy laws and other regulations may apply alongside (or instead of) HIPAA. The most successful healthcare brands are shifting their mindset from asking, "What data can we collect?" to "How do we create value while earning trust?" That means: ✔️ Building privacy into marketing strategy from the beginning—not at the end. ✔️ Vetting ad tech and data partners more carefully. ✔️ Being transparent about how consumer data is collected and used. ✔️ Recognizing that privacy is no longer just a compliance function—it's a brand differentiator. As AI accelerates personalization and consumers become more aware of their data rights, trust will become one of healthcare's most valuable marketing assets. The brands that get privacy right won't just reduce risk—they'll build stronger, longer-lasting relationships with the people they serve. #HealthcareMarketing #PharmaMarketing #DataPrivacy #HIPAA #ConsumerPrivacy #DigitalHealth #AI #MarTech #Trust #MarketingStrategy https://lnkd.in/gnffMWF6
HIPAA Compliance Not Enough for Healthcare Marketers
This title was summarized by AI from the post below.
More Relevant Posts
-
"We are 100% HIPAA compliant." (No, you're probably not.) If your clinical trial site, digital health platform, or pharma company relies on generic website badges, copy-pasted privacy notices, or AI-generated legal policies, you are accumulating massive compliance debt. I sat down with privacy attorney Brandy Bennett (Bennett Law) for an eye-opening episode of the KF Deep Dive. We bypassed the typical HIPAA talking points to focus on the operational realities of US state privacy laws, vendor security, and commercial data contracts. Key Takeaways for Life Sciences Executives: The Myth of Data Certification: There is no official government "HIPAA certification" or "GDPR stamp." Perfect compliance across multi-jurisdictional frameworks is nearly impossible. Claiming complete compliance on a public website creates immediate litigation risk if an enforcement agency opens an audit. Data Counsel The State-Level Enforcement Surge: With over 20 US states deploying comprehensive privacy laws, State Attorneys General are actively auditing consumer-facing digital tools. Using wearables like Fitbits or Oura rings in clinical trials without auditing third-party tracking scripts and adtech integrations can trigger enforcement actions. Clym.io Copy-Pasting & ChatGPT Privacy Notices: Copying another company’s privacy policy or generating one with generative AI is a ticking liability bomb. Regulators and plaintiff attorneys inspect these documents during investigations; inaccuracies serve as direct evidence of deceptive trade practices. No Security, No Cyber Insurance: Relying on willful ignorance ("if we don't look, we won't find a breach") guarantees you will fail underwriting for cyber insurance. Without verified security baselines and insurance coverage, institutional health systems and pharma sponsors will not sign vendor contracts. Control Over Ownership: Stop arguing over who "owns" patient data in commercial negotiations. In modern privacy law, individuals retain rights over their personal information. What matters in contracts is Control, Access, and Specific Purpose Use. TrustArc Privacy isn't just a legal bottleneck—it's the foundation of client and patient trust. If your tech stack collects sensitive health data, build your infrastructure around data minimization from day one. #klf #kulkarnilawfirm #PrivacyLaw #Cybersecurity #HIPAA #DigitalHealth #ClinicalTrials #DataGovernance #CCPA #HealthTech #Compliance
-
"We are 100% HIPAA compliant." (No, you're probably not.) If your clinical trial site, digital health platform, or pharma company relies on generic website badges, copy-pasted privacy notices, or AI-generated legal policies, you are accumulating massive compliance debt. I sat down with privacy attorney Brandy Bennett (Bennett Law) for an eye-opening episode of the KF Deep Dive. We bypassed the typical HIPAA talking points to focus on the operational realities of US state privacy laws, vendor security, and commercial data contracts. Key Takeaways for Life Sciences Executives: The Myth of Data Certification: There is no official government "HIPAA certification" or "GDPR stamp." Perfect compliance across multi-jurisdictional frameworks is nearly impossible. Claiming complete compliance on a public website creates immediate litigation risk if an enforcement agency opens an audit. Data Counsel The State-Level Enforcement Surge: With over 20 US states deploying comprehensive privacy laws, State Attorneys General are actively auditing consumer-facing digital tools. Using wearables like Fitbits or Oura rings in clinical trials without auditing third-party tracking scripts and adtech integrations can trigger enforcement actions. Clym.io Copy-Pasting & ChatGPT Privacy Notices: Copying another company’s privacy policy or generating one with generative AI is a ticking liability bomb. Regulators and plaintiff attorneys inspect these documents during investigations; inaccuracies serve as direct evidence of deceptive trade practices. No Security, No Cyber Insurance: Relying on willful ignorance ("if we don't look, we won't find a breach") guarantees you will fail underwriting for cyber insurance. Without verified security baselines and insurance coverage, institutional health systems and pharma sponsors will not sign vendor contracts. Control Over Ownership: Stop arguing over who "owns" patient data in commercial negotiations. In modern privacy law, individuals retain rights over their personal information. What matters in contracts is Control, Access, and Specific Purpose Use. TrustArc Privacy isn't just a legal bottleneck—it's the foundation of client and patient trust. If your tech stack collects sensitive health data, build your infrastructure around data minimization from day one. #klf #kulkarnilawfirm #PrivacyLaw #Cybersecurity #HIPAA #DigitalHealth #ClinicalTrials #DataGovernance #CCPA #HealthTech #Compliance
-
"We are 100% HIPAA compliant." (No, you're probably not.) If your clinical trial site, digital health platform, or pharma company relies on generic website badges, copy-pasted privacy notices, or AI-generated legal policies, you are accumulating massive compliance debt. I sat down with privacy attorney Brandi M. Bennett, CIPP-US, AIGP (Bennett Law) for an eye-opening episode of the Kulkarni Law Firm, P.C. Deep Dive. We bypassed the typical HIPAA talking points to focus on the operational realities of US state privacy laws, vendor security, and commercial data contracts. Key Takeaways for Life Sciences Executives: 1. The Myth of Data Certification: There is no official government "HIPAA certification" or "GDPR stamp." Perfect compliance across multi-jurisdictional frameworks is nearly impossible. Claiming complete compliance on a public website creates immediate litigation risk if an enforcement agency opens an audit. 2. Data Counsel The State-Level Enforcement Surge: With over 20 US states deploying comprehensive privacy laws, State Attorneys General are actively auditing consumer-facing digital tools. Using wearables like Fitbits or Oura rings in clinical trials without auditing third-party tracking scripts and adtech integrations can trigger enforcement actions. Clym.io 3. Copy-Pasting & ChatGPT Privacy Notices: Copying another company’s privacy policy or generating one with generative AI is a ticking liability bomb. Regulators and plaintiff attorneys inspect these documents during investigations; inaccuracies serve as direct evidence of deceptive trade practices. 4. No Security, No Cyber Insurance: Relying on willful ignorance ("if we don't look, we won't find a breach") guarantees you will fail underwriting for cyber insurance. Without verified security baselines and insurance coverage, institutional health systems and pharma sponsors will not sign vendor contracts. 5. Control Over Ownership: Stop arguing over who "owns" patient data in commercial negotiations. In modern privacy law, individuals retain rights over their personal information. What matters in contracts is Control, Access, and Specific Purpose Use. 6. TrustArc Privacy is the foundation of client and patient trust. If your tech stack collects sensitive health data, build your infrastructure around data minimization from day one. #klf #PrivacyLaw #Cybersecurity #HIPAA #DigitalHealth #ClinicalTrials #DataGovernance #CCPA #HealthTech #Compliance
-
"We are 100% HIPAA compliant." (No, you're probably not.) If your clinical trial site, digital health platform, or pharma company relies on generic website badges, copy-pasted privacy notices, or AI-generated legal policies, you are accumulating massive compliance debt. I sat down with privacy attorney Brandi M. Bennett, CIPP-US, AIGP (Bennett Law) for an eye-opening episode of the KLF Deep Dive. We bypassed the typical HIPAA talking points to focus on the operational realities of US state privacy laws, vendor security, and commercial data contracts. Key Takeaways for Life Sciences Executives: The Myth of Data Certification: There is no official government "HIPAA certification" or "GDPR stamp." Perfect compliance across multi-jurisdictional frameworks is nearly impossible. Claiming complete compliance on a public website creates immediate litigation risk if an enforcement agency opens an audit. Data Counsel The State-Level Enforcement Surge: With over 20 US states deploying comprehensive privacy laws, State Attorneys General are actively auditing consumer-facing digital tools. Using wearables like Apple watches or ŌURA rings in clinical trials without auditing third-party tracking scripts and adtech integrations can trigger enforcement actions. Copy-Pasting & ChatGPT Privacy Notices: Copying another company’s privacy policy or generating one with generative AI is a ticking liability bomb. Regulators and plaintiff attorneys inspect these documents during investigations; inaccuracies serve as direct evidence of deceptive trade practices. No Security, No Cyber Insurance: Relying on willful ignorance ("if we don't look, we won't find a breach") guarantees you will fail underwriting for cyber insurance. Without verified security baselines and insurance coverage, institutional health systems and pharma sponsors will not sign vendor contracts. Control Over Ownership: Stop arguing over who "owns" patient data in commercial negotiations. In modern privacy law, individuals retain rights over their personal information. What matters in contracts is Control, Access, and Specific Purpose Use. Privacy is the foundation of client and patient trust. If your tech stack collects sensitive health data, build your infrastructure around data minimization from day one. #klf #kulkarnilawfirm #PrivacyLaw #Cybersecurity #HIPAA #DigitalHealth #ClinicalTrials #DataGovernance #CCPA #HealthTech #Compliance
-
𝗟𝗮𝘁𝗲𝘀𝘁 𝗶𝗻 𝗣𝗿𝗶𝘃𝗮𝗰𝘆 Ireland moves on Tinder- Ireland's DPC plans to fine Match Group (Tinder's owner) €8-11m over GDPR breaches. Decision expected within weeks. https://lnkd.in/ecbQ7Cwq Who's actually reading your CV? - An estimated 90% of employers now use automated systems to screen or rank job applicants before a human sees them. Fairness and accountability questions here are still wide open. https://lnkd.in/etC2BsCz France's under-15 social media ban, blocked- France's Constitutional Council struck down Macron's bill banning social media for under-15s, citing minors' free expression rights. https://lnkd.in/e-z3uJib Apple softens its ad-tracking prompts- Apple will redesign its iOS consent pop-ups for third-party ad tracking, closing a German antitrust probe. Changes include dropping the word "tracking" and switching the warning color from orange to blue. https://lnkd.in/exzX4dUZ Breach notification templates: is 125 questions too many?- Insurance Europe says the EDPB's draft breach-notification template — 125 questions — is too long and granular, and wants it trimmed to what Article 33 GDPR strictly requires. https://lnkd.in/eNrmCX9D
-
The compliance lead opened the Nevada law and sighed. We already did Washington, can't we just use the same policy? It sounded reasonable. Until they looked closer. Nevada's Senate Bill 370 was modelled after Washington's My Health My Data Act, with the same effective date, similar consent framework and similar consumer health data rights. So copying the Washington approach feels like the obvious move. Except three differences can change your compliance posture. 📌 First is the geofencing radius. Washington prohibits geofencing within 2,000 feet of a healthcare facility while Nevada uses 1,750 feet. That 250-foot difference may look insignificant, but it isn't if you're running the same campaign across multiple states. A campaign compliant in Nevada could still create exposure in Washington. Lexology compares Nevada SB 370 and Washington's MHMDA here: https://lnkd.in/e8W7icaM. 📌 Secondly, no private right of action. Washington allows consumers to sue directly; Nevada does not, and enforcement sits with the Nevada Attorney General. That can create false comfort. No private right of action does mean no risk, it means the enforcement pathway is different. 📌 Third, and this is the one to pay closest attention to. Nevada exempts HIPAA-covered entities from SB 370, not simply HIPAA-covered data but the entity itself. That distinction matters because a hospital or covered physician practice may fall within the exemption. But a wellness app, consumer fertility platform, health-data analytics company, or health-adjacent marketing platform may not. If you are not a HIPAA-covered entity or business associate, you cannot assume your existing HIPAA compliance posture protects you from SB 370. Bass Berry & Sims breaks down Nevada's HIPAA entity exemption here: https://lnkd.in/eikE-eh2 If Nevada is on your compliance roadmap, check three things: 📌 Does your Washington policy actually account for Nevada's different requirements? 📌 Does your company genuinely qualify for Nevada's HIPAA entity exemption? 📌 Have you mapped the consumer health data you collect from Nevada residents, including location, biometric, wellness, and inferred health information? Nevada looks like Washington from a distance. But up close, the differences are exactly where the exposure lives. If you were reviewing a healthtech company's compliance posture, which of these three would you audit first, geofencing, enforcement, or the HIPAA exemption?
-
-
Great summary Ron. Australia's AI regulations will advance rapidly, and it's something our industry must keep a close eye on. #AI #privacy #regulation #insurance #risk
Yesterday six ministers from the Albanese Government outlined Australia's AI consumer safety priorities as part of the National AI Plan and there will be implicatio for insurers. The five key areas identified are: 1. A legislated Digital Duty of Care, which places the responsibility on AI companies to incorporate safety by design and proactively mitigate harm. 2. A second tranche of privacy reform aimed at strengthening and modernizing data protection laws. 3. Ensuring AI safety in the workplace through the establishment of the tripartite AI Workplace and Employment Forum. 4. Exploring consumer law options to address emerging risks, particularly concerning retail surveillance pricing and agentic commerce. 5. Developing a framework to regulate automated decision-making within federal agencies. These areas are critical as they focus on consumer risk, particularly the novel aspects of retail surveillance pricing and agentic commerce. The forthcoming new Privacy Principles may have significant implications for insurer pricing, with the possibility of further developments. It is important to note that long before the advent of AI, consumers encountered various risks such as mispriced products, unfair terms, opaque commissions, claims disputes, and data breaches. Existing frameworks like the Australian Consumer Law, ASIC, the ACCC, the Privacy Act, AFCA, the General Insurance Code of Practice, and the unfair contract terms regime already address many of these issues. Much of the concern surrounding AI may be rooted in familiar risks that have taken on new forms. Therefore, the evaluation for each of these five workstreams is straightforward: does it address a genuine gap that existing laws do not cover, or does it merely replicate what is already in place? Getting this wrong could lead to excessive regulations that increase the cost of doing business, hinder beneficial innovation, and provide minimal additional consumer protection. https://lnkd.in/g73Ww_Fj
-
An automated decision can have real consequences. The Dutch AP has fined Uber €825m over historic automated driver-account deactivations. Uber says it will appeal. The practical takeaway: when automation can materially affect someone’s work or income, human safeguards need to work in practice. That means a reviewer with enough information, authority and time to assess the case, plus a clear route to challenge the outcome. Our latest article sets out five controls to test now. #GDPR #DataProtection https://lnkd.in/e5Ecfipp
-
𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐭𝐡𝐞 "𝐂𝐨𝐧𝐬𝐞𝐧𝐭 𝐌𝐚𝐧𝐚𝐠𝐞𝐫" 𝐔𝐧𝐝𝐞𝐫 𝐭𝐡𝐞 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥 𝐃𝐚𝐭𝐚 𝐏𝐫𝐨𝐭𝐞𝐜𝐭𝐢𝐨𝐧 (𝐃𝐏𝐃𝐏) 𝐀𝐜𝐭, 𝟐𝟎𝟐𝟑 — 𝐀𝐧𝐝 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬 𝐟𝐨𝐫 𝐘𝐨𝐮 A new concept in Indian data protection law, explained in plain words with the actual provisions. 𝟭. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗶𝘁? Today, if 5 companies hold your data, you manage consent with each one separately — different app, different login. Section 2(g) of the DPDP Act creates a Consent Manager — a company registered with the Data Protection Board that gives you ONE platform to give, review, or withdraw consent across all of them. It's legally "𝐝𝐚𝐭𝐚-𝐛𝐥𝐢𝐧𝐝" — it never sees your actual data (no bank balance, no medical records). It only handles the "yes/no" permission slip. 𝟮. 𝗪𝗵𝗼 𝗰𝗮𝗻 𝗯𝗲 𝗮 𝗖𝗼𝗻𝘀𝗲𝗻𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿? Only a company incorporated in India under the Companies Act, 2013 — not a trust, LLP, partnership, or foreign entity. Part A, First Schedule (DPDP Rules, 2025) also requires it to have: → Net worth of at least ₹2 crore → Sufficient technical, operational and financial capacity → Directors/KMP with a clean reputation → A certified, interoperable platform meeting Board standards → Operations shown to serve Data Principals' interests 𝟯. 𝗪𝗵𝗮𝘁 𝗺𝘂𝘀𝘁 𝗶𝘁 𝗱𝗼? (Part B) → Ensure data passing through is "not readable by it" → Keep consent records for 7 years, accessible on request → Never sub-contract its obligations → Act in a fiduciary capacity — for you, not the company → Avoid conflict of interest with Data Fiduciaries at director/KMP level 𝟰. 𝗜𝘀 𝗶𝘁 𝗺𝗮𝗻𝗱𝗮𝘁𝗼𝗿𝘆? For you, as a Data Principal — no. Section 6(7) says "𝗺𝗮𝘆": using one is your choice. You can keep dealing with each company directly. For a company offering this service — yes. Section 6(9) makes Board registration compulsory. One catch: the mechanism only works if your bank, insurer etc. are "onboarded" onto the Consent Manager's platform. But neither Part A nor Part B forces a Data Fiduciary to onboard — that gap may get addressed later through Board standards. 𝟱. 𝗔𝗻 𝗲𝘅𝗮𝗺𝗽𝗹𝗲 Data Principal X has given her data to her bank, insurer, and a food delivery app. Today, she opens 3 apps to manage consent separately. With a Consent Manager, X opens just ONE platform — switching off marketing consent for the food app in one tap, while banking and insurance permissions stay untouched. The platform itself still never sees her data. If you've used an Account Aggregator for bank statements — same architecture, now extended to all personal data. Rule 4 comes into force 13 November 2026. Several practical questions — including Data Fiduciary onboarding — remain open. #DPDP #DataProtection #ConsentManager #CorporateGovernance #CompanySecretary #DataPrivacy #GeneralCounsel
